Evidence map›Paper›PMID 40761879›Full record

ArticleArchive of clinical cases2025

MASLD risk prediction in IBD: development of two tailored clinical scores.

Remus Stafie, Robert Nastasa, Carol Stanciu, Cristina Muzica, Sebastian Zenovia, Ana Maria Singeap, Mihaela Dimache, Anca Victorita Trifan

Abstract read
In one paragraph

Article in Archive of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Remus StafieGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.ORCID https://orcid.org/0000-0003-1460-6559
Robert NastasaGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.ORCID https://orcid.org/0000-0002-8678-0663
Carol StanciuInstitute of Gastroenterology and Hepatology, "Sf. Spiridon" University Hospital, Iasi, Romania.ORCID https://orcid.org/0000-0002-6427-4049
Cristina MuzicaGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.ORCID https://orcid.org/0000-0003-0891-5961
Sebastian ZenoviaGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.ORCID https://orcid.org/0000-0003-0441-3980
Ana Maria SingeapGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.ORCID https://orcid.org/0000-0001-5621-548X
Mihaela DimacheGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Anca Victorita TrifanGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.ORCID https://orcid.org/0000-0001-9144-5520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in patients with inflammatory bowel disease (IBD), but accurate, disease-specific predictive tools are lacking. This study aimed to identify key risk factors and develop tailored prediction models for MASLD in IBD patients.

Indexed as

Gut-liver axisHepatic steatosisIBDMASLDRisk prediction model

Identifiers

PMID40761879
PMCPMC12317427

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.